JB Li
YOU?
Author Swipe
View article: 67MO Neoadjuvant and adjuvant toripalimab in high-risk locoregionally advanced nasopharyngeal carcinoma: A randomised, double-blind, placebo-controlled, phase II trial
67MO Neoadjuvant and adjuvant toripalimab in high-risk locoregionally advanced nasopharyngeal carcinoma: A randomised, double-blind, placebo-controlled, phase II trial Open
Patients (pts) with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) with high pretreatment plasma Epstein–Barr virus (EBV) DNA remain at high risk for recurrence after platinum-based concurrent chemoradiotherapy(CCRT). The purpos…